Karine Tawagi, MD

home / authors / karine-tawagi-md

Articles

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, University of Illinois

ASCO 2024 Plenary: NADINA Trial Neoadjuvant Ipi/Nivo vs Adjuvant Nivo for Resectable Stage III Melanoma

Samantha A. Armstrong, MD;Karine Tawagi, MD
August 12th 2024

Drs Armstrong and Tawagi discuss the NADINA trial of neoadjuvant nivolumab/ipilimumab vs adjuvant nivolumab in resectable, macroscopic, stage III melanoma.

Read More

Samantha A. Armstrong, MD, hematologist/oncologist, assistant professor, clinical medicine, Indiana University Health; Karine Tawagi, MD, hematologist/oncologist, assistant professor, clinical medicine, the University of Illinois

ASCO 2024 Plenary: ADRIATIC Trial in Limited-Stage Small Cell Lung Cancer

Samantha A. Armstrong, MD;Karine Tawagi, MD
July 8th 2024

OncLive On Air partners with Two Onc Docs to bring insights on the ADRIATIC trial, data from which were presented at the 2024 ASCO Annual Meeting.

Read More

Samantha A. Armstrong, MD; Karine Tawagi, MD

ASCO 2024 Plenary: LAURA Trial in Unresectable Stage III EGFRm NSCLC

Samantha A. Armstrong, MD;Karine Tawagi, MD
June 10th 2024

OncLive On Air partners with Two Onc Docs to bring insights on primary data from the LAURA trial, which were presented at the 2024 ASCO Annual Meeting.

Read More

Latest Updated Articles

Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Published: August 22nd 2024 | Updated: August 29th 2024
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Published: August 6th 2024 | Updated: August 19th 2024
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
OncLive’s August Roundup of Key FDA Approvals in Oncology
Published: September 4th 2024 | Updated: September 8th 2024
OncLive’s August Roundup of Key FDA Approvals in Oncology
Paula Rodriguez-Otero, MD, PhD
Published: June 4th 2024 | Updated: September 8th 2024
D-VRd Boosts MRD-Negativity Rates in Newly Diagnosed, Transplant-Eligible Multiple Myeloma